Evidence map›Paper›PMID 36425152›Full record

ArticleMediterranean journal of hematology and infectious diseases2022

Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Study.

Ibrahim Halil Acar, Sebnem Izmir Guner, Muzeyyen Aslaner Ak, Mesut Gocer, Erman Ozturk, Figen Atalay, Gulden Sincan, Aysun Senturk Yikilmaz, Omer Ekinci, Idris Ince and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of hematology and infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 1 country.

Ibrahim Halil AcarAdana Cukurova University, Faculty of Medicine, Hematology Department, Adana, Turkey.
Sebnem Izmir GunerIstanbul Gelisim University, Memorial Sisli Hospital Hematology&Bone Marrow Transplantation Unite, Istanbul, Turkey.
Muzeyyen Aslaner AkZonguldak Bulent Ecevit University, Faculty of Medicine, Hematology Department, Zonguldak, Turkey.
Mesut GocerHealth Sciences University, Antalya Training and Research Hospital, Hematology Clinic, Antalya, Turkey.
Erman OzturkIstanbul Medeniyet University, Faculty of Medicine, Hematology Department, Istanbul, Turkey.
Figen AtalayBaskent University, School of Medicine, Department of Hematology, Ankara, Turkey.
Gulden SincanAtaturk University, Faculty of Medicine, Department of Hematology, Erzurum, Turkey.
Aysun Senturk YikilmazDenizli Goverment Hospital, Hematology Clinic, Denizli, Turkey.
Omer EkinciMedicana International Istanbul, Adult Hematology and Bone Marrow Transplantation Center, Istanbul, Turkey.
Idris InceDr. Ersin Arslan Training and Research Hospital, Department of Hematology, Gaziantep, Turkey.
Emine GulturkBakirkoy Dr. Sadi Konuk Training and Research Hospital, Hematology Clinic, Istanbul, Turkey.
Nazli DemirSisli Hamidiye Etfal Training and Research Hospital, Hematology Clinic, Istanbul, Turkey.
Ali DoganVan Yuzuncu Yil University, Faculty of Medicine, Department of Hematology, Van, Turkey.
Yildiz IpekIstanbul Kartal Dr. Lutfi Kirdar City Hospital, Hematology Clinic, Istanbul, Turkey.
Birol GuvencAdana Cukurova University, Faculty of Medicine, Hematology Department, Adana, Turkey.
Cukurova University · TRAtatürk University · TRBakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi · TRBaşkent University · TRBülent Ecevit University · TRDenizli Devlet Hastanesi · TRDr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi · TRGaziantep Children's Hospital · TRİstanbul Gelişim Üniversitesi · TRIstanbul Medeniyet University · TRSağlık Bilimleri Üniversitesi · TRŞişli Etfal Eğitim ve Araştırma Hastanesi · TRVan Yüzüncü Yıl Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Patients with hematological malignancies have a high risk of mortality from coronavirus disease 2019 (COVID-19). This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematological malignancies and to determine risk factors associated with all-cause mortality. Methods: A multicenter, observational retrospective analysis of patients with hematological malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study. Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematological malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p<0.001) and had more comorbidities (p<0.05). In addition, there were significantly more patients with low lymphocyte percentage (p<0.001), thrombocytopenia (p<0.001), and high CRP (p<0.001) in the non-survived patients. Age ≥ 65years (p=0.017), cardiac comorbidities (p=0.041), and continuation of ongoing active therapy for hematological cancer (p<0.001) were the independent risk factors for the prediction of mortality. Conclusions: In patients with hematological malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Older age, cardiac diseases, and continuation of ongoing active therapy for hematological cancer are the independent risk factors for mortality in hematological malignancy patients with COVID-19.

Indexed as

COVID-19 virus diseaseHematologic malignanciesMortality

Identifiers

PMID36425152
PMCPMC9652004
OpenAlexW4307687219

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.